Thirty- versus ten-day diazepam treatment ...
Document type :
Article dans une revue scientifique: Article original
PMID :
Permalink :
Title :
Thirty- versus ten-day diazepam treatment for alcohol detoxification and a comparison of drinking patterns, craving, and anxiety for up to 12 weeks: a
Author(s) :
Simioni, Nicolas [Auteur]
Labreuche, Julien [Auteur]
Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS]
Behal, Helene [Auteur]
Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS]
Cottencin, Olivier [Auteur]
Laboratoire Sciences Cognitives et Sciences Affectives - UMR 9193 [SCALab]
Sciences Cognitives et Sciences Affectives (SCALab) - UMR 9193
Laboratoire Sciences Cognitives et Sciences Affectives - UMR 9193 [SCALab]
Rolland, Benjamin [Auteur]
Labreuche, Julien [Auteur]
Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS]
Behal, Helene [Auteur]
Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS]
Cottencin, Olivier [Auteur]
Laboratoire Sciences Cognitives et Sciences Affectives - UMR 9193 [SCALab]
Sciences Cognitives et Sciences Affectives (SCALab) - UMR 9193
Laboratoire Sciences Cognitives et Sciences Affectives - UMR 9193 [SCALab]
Rolland, Benjamin [Auteur]
Journal title :
Journal of Clinical Psychopharmacology
Abbreviated title :
J. Clin. Psychopharmacol.
Volume number :
37
Pages :
722-728
Publication date :
2017-12-01
ISSN :
0271-0749
English keyword(s) :
alcohol dependence
alcohol cessation
diazepam
benzodiazepine
detoxification treatment
relapse
Mesh:Alcoholism/blood
Mesh:Humans
Mesh:GABA Modulators/pharmacology*
Mesh:GABA Modulators/administration & dosage
Mesh:Female
Mesh:Drug Administration Schedule
Mesh:Diazepam/pharmacology*
Mesh:Diazepam/administration & dosage
Mesh:Craving/drug effects*
Mesh:Anxiety/drug therapy*
Mesh:Alcoholism/drug therapy*
Mesh:Male
Mesh:Alcohol Abstinence*
Mesh:Adult
Mesh:Transferrin/analysis
Mesh:Transferrin/analogs & derivatives
Mesh:Proof of Concept Study
Mesh:Pilot Projects
Mesh:Outcome Assessment (Health Care)*
Mesh:Middle Aged
alcohol cessation
diazepam
benzodiazepine
detoxification treatment
relapse
Mesh:Alcoholism/blood
Mesh:Humans
Mesh:GABA Modulators/pharmacology*
Mesh:GABA Modulators/administration & dosage
Mesh:Female
Mesh:Drug Administration Schedule
Mesh:Diazepam/pharmacology*
Mesh:Diazepam/administration & dosage
Mesh:Craving/drug effects*
Mesh:Anxiety/drug therapy*
Mesh:Alcoholism/drug therapy*
Mesh:Male
Mesh:Alcohol Abstinence*
Mesh:Adult
Mesh:Transferrin/analysis
Mesh:Transferrin/analogs & derivatives
Mesh:Proof of Concept Study
Mesh:Pilot Projects
Mesh:Outcome Assessment (Health Care)*
Mesh:Middle Aged
HAL domain(s) :
Sciences du Vivant [q-bio]
Sciences cognitives
Sciences cognitives
English abstract : [en]
OBJECTIVE: The aim of this study was to evaluate whether a prolonged detoxification treatment could decrease the relapse rate at 3 months after alcohol cessation in alcohol-dependent individuals through decreasing the ...
Show more >OBJECTIVE: The aim of this study was to evaluate whether a prolonged detoxification treatment could decrease the relapse rate at 3 months after alcohol cessation in alcohol-dependent individuals through decreasing the levels of postdetoxification craving and anxiety. METHODS: Twenty-six adult patients with alcohol dependence (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision) who began an outpatient alcohol cessation program with an initial drinking goal of abstinence were enrolled in a 3-month, parallel, randomized (1:1 ratio), controlled, open-label, pilot trial. Participants were randomized to receive a detoxification treatment of diazepam with a duration of 30 (n = 12) or 10 days (n = 14). All participants received BRENDA-based psychotherapy during follow-up. RESULTS: No significant between-group difference in relapse to any drinking was found at 3 months (P = 0.20). However, relapse to any heavy drinking at 3 months and regular drinking or heavy drinking during follow-up were significantly lower in the 30-day diazepam group (P = 0.009, P = 0.049, and P = 0.004, respectively). These differences were corroborated by significant differences in the alcohol-specific biological marker carbohydrate deficient transferrin at 3 months. Participants in the 30-day diazepam group also displayed significantly lower scores for alcohol craving (P = 0.007), self-reported anxiety (P = 0.024), and clinician-assessed anxiety (P = 0.002) throughout the follow-up. No serious adverse event was reported during the study. CONCLUSIONS: This study provides an evidence-based rationale for a double-blind, randomized, placebo-controlled trial to confirm the efficacy of such a procedure on short-term and mid-/long-term drinking outcomes after alcohol cessation in alcohol-dependent individuals.Show less >
Show more >OBJECTIVE: The aim of this study was to evaluate whether a prolonged detoxification treatment could decrease the relapse rate at 3 months after alcohol cessation in alcohol-dependent individuals through decreasing the levels of postdetoxification craving and anxiety. METHODS: Twenty-six adult patients with alcohol dependence (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision) who began an outpatient alcohol cessation program with an initial drinking goal of abstinence were enrolled in a 3-month, parallel, randomized (1:1 ratio), controlled, open-label, pilot trial. Participants were randomized to receive a detoxification treatment of diazepam with a duration of 30 (n = 12) or 10 days (n = 14). All participants received BRENDA-based psychotherapy during follow-up. RESULTS: No significant between-group difference in relapse to any drinking was found at 3 months (P = 0.20). However, relapse to any heavy drinking at 3 months and regular drinking or heavy drinking during follow-up were significantly lower in the 30-day diazepam group (P = 0.009, P = 0.049, and P = 0.004, respectively). These differences were corroborated by significant differences in the alcohol-specific biological marker carbohydrate deficient transferrin at 3 months. Participants in the 30-day diazepam group also displayed significantly lower scores for alcohol craving (P = 0.007), self-reported anxiety (P = 0.024), and clinician-assessed anxiety (P = 0.002) throughout the follow-up. No serious adverse event was reported during the study. CONCLUSIONS: This study provides an evidence-based rationale for a double-blind, randomized, placebo-controlled trial to confirm the efficacy of such a procedure on short-term and mid-/long-term drinking outcomes after alcohol cessation in alcohol-dependent individuals.Show less >
Language :
Anglais
Audience :
Internationale
Popular science :
Non
Administrative institution(s) :
CHU Lille
CNRS
Inserm
Université de Lille
CNRS
Inserm
Université de Lille
Collections :
Research team(s) :
Troubles cognitifs dégénératifs et vasculaires
Submission date :
2019-11-27T13:03:07Z
2020-04-21T10:37:59Z
2020-04-21T10:37:59Z